Joint Research Center for Hematologic Oncology was jointly established by the School of Medicine Tsinghua University and Beijing Lu Daopei Institute of Hematology Co., Ltd. in October 2018. The center aims to adopt a combined research model of "basic research" and "clinical practice," focusing on studying the pathogenesis and relapse prevention treatment methods of refractory leukemia, multiple myeloma, malignant lymphoma, and other hematologic cancers. The two parties collaborate on various research projects in areas such as pathology, medical testing, and clinical treatment of hematologic cancers, with a particular emphasis on the pathogenesis and treatment methods for refractory and relapsed hematologic cancers, achieving bidirectional translation between basic research and clinical research.

During the first three-year phase of cooperation, the two parties initiated research projects centered around innovative STAR-T cell therapy based on clinical issues. Several innovative research projects are currently underway or in submission, and some results have already been submitted for patent applications. The research center has launched multiple clinical trials, proposing new ideas and methods for the detection and treatment of relapsed and refractory hematologic cancers.